Objective: Human papillomavirus (HPV) infections are widespread in all human populations, and a large number of studies have demonstrated a relationship between high-risk (HR)-HPV infections and cervical intraepithelial neoplasia or invasive cervical cancer. To the best of our knowledge, no independent study clearly demonstrates the importance of the quantity of residual liquid after cytology in terms of sensitivity for HR-HPV detection. Study Design: We conducted a study to assess the relationship between the liquid-based cytology volume and the sensitivity of the hybrid capture 2 test for the detection of HR-HPV in 23 cytological high-grade squamous intraepithelial lesions with a cervical intraepithelial neoplasia grade 2 or worse protocol on biopsy. Results: Although the sensitivity of the tests showed no statistically significant differences, we still found a significant variation in the median values of relative light units/control according to the amount of liquid used. Conclusions: If 2 ml of liquid is used, this could lead to false negatives when the value of relative light units/control is only slightly greater than 1. The fact that we found a lower viral load at 2 versus 4 or 8 ml was also important in terms of predicting the evolution of cervical lesions. We recommend using at least 4 ml of the PreservCyt solution for HR-HPV detection with the hybrid capture 2 test.

Keywords:
Cervix, Human papillomavirus, Cytological liquid volume, Smears, Cytology
1.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–19.
2.
Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S: Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958–964.
3.
Tiews S, Steinberg W, Schneider W, Hanrath C: Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data. J Clin Virol 2009;46:S11–S15.
4.
Dunn JE Jr, Schweitzer V: The relationship of cervical cytology to the incidence of invasive cervical cancer and mortality in Alameda County, California, 1960 to 1974. Am J Obstet Gynecol 1981;139:868–876.
5.
Parkin DM, Nguyen-Dinh X, Day NE: The impact of screening on the incidence of cervical cancer in England and Wales. Br J Obstet Gynaecol 1985;92:150–157.
6.
Duguid HL, Duncan ID, Currie J: Screening for cervical intraepithelial neoplasia in Dundee and Angus 1962–81 and its relation with invasive cervical cancer. Lancet 1985;ii:1053–1056.
7.
Dalstein V, Riethmuller D, Prétet JL, Le Bail Carval K, Sautière JL, Carbillet JP, Kantelip B, Schaal JP, Mougin C: Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106:396–403.
8.
Zhao FH, Hu SY, Bian JJ, Liu B, Peck RB, Bao YP, Pan QJ, Frappart L, Sellors J, Qiao YL: Comparison of ThinPrep and SurePath liquid-based cytology and subsequent human papillomavirus DNA testing in China. Cancer Cytopathol 2011;119:387–394.
9.
Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, et al: Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235–240.
10.
van Duin M, Snijders PJ, Schrijnemakers HF, Voorhorst FJ, Rozendaal L, Nobbenhuis MA, van den Brule AJ, Verheijen RH, Helmerhorst TJ, Meijer CJ: Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer 2002;98:590–595.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.